Therapy Directory

Nivolumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Nivolumab as a study intervention. Browse Nivolumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1209

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions: Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo); Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year to 39 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma, Brain Metastases
Interventions: Ipilimumab, Nivolumab + Relatlimab FDC; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer
Interventions: Implantable Microdevice (IMD); Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Ipilimumab, Nivolumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oligoprogressive
Interventions: IMSA101, Immune checkpoint inhibitor, PULSAR; Drug · Radiation
Lead sponsor: ImmuneSensor Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 14
States / cities: Irvine, California • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions: Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Prostate Cancer, Recurrent Prostate Cancer
Interventions: Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Anchorage, Alaska • Los Angeles, California • Boise, Idaho + 3 more

Conditions: Urothelial Carcinoma Bladder, Bladder Cancer
Interventions: Concurrent Immunotherapy and Radiation Therapy; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Nivolumab, HuMax-IL8; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Interventions: Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin, Capecitabine; Drug
Lead sponsor: I-Mab Biopharma US Limited; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Goodyear, Arizona • Duarte, California • Boston, Massachusetts

About this Nivolumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Nivolumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Nivolumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Nivolumab clinical trials

Filter and sort this therapy

Live official records

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Drug Screening Using IMD in Bladder Cancer

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Drug Screening Using Novel IMD in Renal Cell Carcinoma

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

About this Nivolumab clinical trials directory page